News | January 12, 2026
Evotec subsidiary bags Gates Foundation grant to expand global access to biologics
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The resubmission of BLA for MOLBREEVI names Fujifilm as the drug substance manufacturer
Harbour BioMed brings advanced antibody discovery platforms to the table
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
Subscribe To Our Newsletter & Stay Updated
